Search
Now showing items 1-2 of 2
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to < 12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
(Hepatology, 2019-08)
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin ...
COVID-19 Exacerbates Insulin Resistance During Diabetic Ketoacidosis in Pediatric Patients With Type 1 Diabetes
(Diabetes Care, 2022-10)
OBJECTIVE Although mortality from coronavirus disease 2019 (COVID-19) among youth with type 1 diabetes is rare, severe acute respiratory syndrome coronavirus 2 is associated with increased pediatric hospitalizations for ...